000950.SZ
重药控股
SZSE · Healthcare · F 批发零售 · CN
CNY 5.41
−1.28%Aug 25, 2026, 10:36 UTC
Chongqing Pharmaceutical Holding Co., Ltd. announced its first-half 2026 results: net profit attributable to shareholders was 254 million yuan, down 9.85% year-on-year, with revenue of 40.132 billion yuan, down 2.57%.
Source:Aug 4, 2026, 09:14 UTC
Chongqing Pharmaceutical Holdings and its controlling subsidiaries have newly disclosed litigation and arbitration matters not previously disclosed within the past twelve months, with a total involved amount of 1.289 billion yuan, accounting for 11.17% of the company's most recent audited net assets attributable to the parent company.
Source:Jul 23, 2026, 06:30 UTC
Chongqing Pharmaceutical Holding and Tangchuan Biotechnology Co., Ltd. signed a strategic cooperation agreement on the full functional sugar alcohol industry chain to jointly develop a full-cycle intestinal health product matrix.
Source:Jul 23, 2026, 03:07 UTC
Chongqing Pharmaceutical Holding and Hansoh Pharmaceutical Group officially launched the Xinfengyi project strategic partnership, covering 9 provinces and municipalities, to integrate resources and deepen collaboration in market access and emerging businesses.
Source: